Targeting Group 4 medulloblastoma via Musashi1-cell cycle inhibition
Despite recent progress in medulloblastoma treatment, two main problems remain. High risk groups 3 and 4 medulloblastoma patients still show a high rate of mortality. Even in the case of success, patients are frequently left with devastating neurocognitive and other sequelae. Therefore, more effective and less aggressive therapies are still in demand. ...